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RNA interference (RNAi) is a natural cellular mechanism that inhibits gene expression 
in a sequence-specific manner. In the last decade, RNAi has become a cornerstone 
in basic biological systems research and drug development efforts. The RNAi-based 
manipulation of mammalian cells facilitates target identification and validation; assists 
in identifying human disease etiologies; and expedites the development of treatments 
for infectious diseases, cancer, and other conditions. Several RNAi-based approaches 
are currently undergoing assessment in phase I and II clinical trials. However, RNAi-
associated immune stimulation might act as a hurdle to safe and effective RNAi, 
particularly in clinical applications. The induction of innate immunity may originate from 
small interfering RNA (siRNA) sequence-dependent delivery vehicles and even the RNAi 
process itself. However, in the case of antagonistic cancers and viral infection, immune 
activation is beneficial; thus, immunostimulatory small interfering RNAs were designed 
to create bifunctional small molecules with RNAi and immunostimulatory activities. This 
review summarizes the research studies of RNAi-associated immune stimulation and the 
approaches for manipulating immunostimulatory activities.
Keywords: RNA interference, small interfering RNA, innate immunity, immunostimulatory RNA, immunostimulatory 
small interfering RNAs
iNTRODUCTiON
RNA interference (RNAi) is a post-transcriptional gene regulation mechanism by which small inter-
fering RNAs (siRNAs) induce the sequence-specific degradation of homologous messenger RNA 
(mRNA) (1). In the past 16 years, RNAi has been widely used in basic biological research and drug 
development processes. In particular, significant progress has been achieved in the fields of cancer 
(2), leukemia (3), hepatitis B virus (HBV), and human immunodeficiency virus infections (4). There 
are currently 45 registered studies.1 Clinical trials using siRNA-based drugs have shown efficacy in 
the treatment of HBV infection (5), respiratory syncytial virus infection (6), and cancer.
The data from a phase IIa clinical study presented at the AASLD Liver Meeting in 2015 demon-
strated that ARC-520, a targeted RNAi therapeutic against HBV, effectively reduced HBV surface 
antigen levels up to a maximum mean 1.5 logs (96.8%) and 1.9 logs (99%) in treatment-naïve patients 
who tested positive for HBV e-antigen. The direct sustained antiviral effect of a single dose lasted 
1 https://clinicaltrials.gov.
FiGURe 1 | Schematic representation of RNA interference (RNAi)-
associated immunostimulation. The retinoic acid-inducible gene-I (RIG-I)/
melanoma differentiation-associated protein 5 (MAD5), toll-like receptor (TLR) 
3, TLR7/8, and PKR signaling pathways can recognize isiRNA; on the other 
hand, the RNAi process generates small RNAs that may activate PKR, TLR3, 
and TLR7/8, inducing type I interferon (IFN) and pro-inflammatory cytokine 
production. isiRNA, immunostimulatory siRNA.
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57 days. ARC-520 has been examined in multiple studies aimed at 
producing a functional cure for HBV infection (7). Unfortunately, 
the clinical trials with ARC-520 have been recently stopped by 
FDA due to the occurrence of sever adverse effect.
In siRNA-based technologies, many studies have reported 
innate immune stimulation by siRNA and/or the siRNA deliv-
ery vehicle (8–11). Various features of the siRNA structure, 
sequence, and delivery mode have contributed to the immune 
stimulation effect, leading to undesired effects and the misinter-
pretation of experimental results, i.e., immunological off-target 
effects (12). Sledz et al. observed a twofold induction of 52 of the 
850 putative interferon (IFN)-stimulated genes (ISGs) upon the 
use of synthetic siRNAs (13). Bridge et al. reported that the use 
of DNA vectors that encoded small hairpin RNAs upregulated 
27 ISGs. Of note, these authors observed that oligoadenylate 
synthase-1 (OAS1) was upregulated by 50-fold using one siRNA 
vector and 500-fold using two vectors (14). However, neither 
the silencing vectors nor the synthetic siRNAs was effective, 
suggesting that some aspect of both the siRNA sequence and 
the delivery method is required to upregulate IFN. Most of the 
published data of the immune-related side effects of various 
reagents observed in in vitro and in vivo experiments that may 
be helpful in the development and use of microRNA (miRNA)- 
and RNAi-based methods are stored in the RNAimmuno 
database2 (15).
In a previous study in primary woodchuck hepatocytes (PWHs) 
with woodchuck hepatitis virus (WHV) infection, we observed that 
RNAi-mediated WHV suppression upregulated the expressions 
of Myxovirus resistance A (MxA) and major histocompatibility 
complex I (MHC-I) genes (16), while further studies revealed that 
the RNAi process enhances innate immune responses via multiple 
signaling pathways in primary hepatocytes (17).
siRNA-ASSOCiATeD iMMUNe 
STiMULATiON
Molecular Foundation of Single-Stranded 
RNA (ssRNA) And Double-Stranded RNA 
(dsRNA) immune Sensing
Four or more signaling pathways recognize RNA molecules 
and induce the production of type I IFN and pro-inflammatory 
cytokines, including the retinoic acid-inducible gene-I (RIG-I)/
melanoma differentiation-associated protein 5 (MDA5), toll-
like receptor (TLR) 3, TLR7/8, and dsRNA-dependent protein 
kinase (PKR) pathways (Figure 1). MDA5 recognizes long RNA 
molecules, while RIG-I detects the emerging 5′-triphosphate 
moiety of viral transcripts or genomes of negative-sense ssRNA 
viruses (18), dsRNAs that are 300–1,000 bp long (19), short blunt-
ended dsRNA (siRNA ~21 nucleotides long) (19), and RNase 
L-generated small self-RNAs (20). Thus, the RIG-I/MDA5 path-
way recognizes ssRNA, dsRNAs, siRNAs, and small self-RNAs; 
TLR3 recognizes dsRNA; and TLR7 and TLR8 identify GU-rich 
2 http://rnaimmuno.ibch.poznan.pl.
short ssRNA as well as small manmade molecules such as 
nucleoside analogs and midazoquinolines. These ligands bind to 
TLR3, and TLR7/8 subsequently activates downstream signaling 
molecules, including nuclear transcription factor (NF)-κB, IFN 
regulatory factor (IRF) 1/3/7, c-Jun N-terminal protein kinase, 
and mitogen-activated protein kinase, activating type I IFNs, 
chemokines, pro-inflammatory cytokines, antibodies, adhesion 
molecules, MHCs, and costimulatory molecules (21). PKR was 
first identified as a sensor that functions in a non-sequence-
specific fashion with long (>33 bp) dsRNA sequences, causing 
activation. Some cellular and viral RNAs containing multiple 
shorter dsRNA sections and non-Watson–Crick structures can 
also regulate PKR (22, 23).
Single- and Double-Stranded  
siRNA-induced Sequence-Dependent 
inflammatory Cytokine and  
iFN Activations
Sioud demonstrated that single- and double-stranded siRNAs 
(sense or antisense strands) could induce interleukin-6 (IL-6) and 
tumor necrosis factor-α (TNF-α) in adherent peripheral blood 
mononuclear cells (PBMCs). The fact that only certain sequences 
induced inflammatory responses suggested that the siRNA-
associated immunostimulatory effects were sequence-dependent. 
TNF-α, IL-6, and IFN-α inductions were chloroquine-sensitive 
and likely dependent on endosomal TLR signaling, specifically 
TABLe 1 | Characteristics of immunostimulatory RNAs.
Characteristic Signaling pathway Cytokines Reference
5′-UGUGU-3′ motif Toll-like receptor 
(TLR) 8
Interferon (IFN)-α (27, 28)
5′-GUCCUUCAA-3′ 
motif
TLR7/8 IFN-α (25)
GU or AU rich TLR7/8 IFN-α, tumor necrosis 
factor (TNF)-α
(27, 28)
Uracil repeats TLR7 IFN-α, interleukin-6, 
TNF-α
(30–33)
Blunt ended Retinoic acid-inducible 
gene-I (RIG-I)
Type I IFN, p56 (34)
5′-Triphosphate RIG-I IFN-α, IFN-β (36–38)
MicroRNA-like small 
interfering RNA
TLR7/8 IFN-α, TNF-α (39)
The sequence motifs and the corresponding stimulated cellular signaling pathways are 
given.
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TLR8 (24). TLR7 facilitates the response in mice versus TLR7/8 in 
humans. In fact, a study in TLR7-knockout mice demonstrated no 
siRNA-related response (25). Microarray analysis demonstrated 
that >400 genes were significantly altered in PBMCs in response 
to double- or single-stranded siRNAs (26).
Two classes of single-stranded TLR7/8 and TLR8 RNA ago-
nist classes were identified that demonstrated species specificity, 
diverse target cells, and immune response profiles. These specific 
TLR8 RNA configurations communicate via TLR8 but do not 
induce IFN-α from TLR7-expressing plasmacytoid dendritic 
cells (PDCs); however, they induce Th1-like pro-inflammatory 
cytokine secretion by TLR8-expressing monocytes and myeloid 
dendritic cells (DCs). By contrast, RNA sequences containing 
the TLR7/8 motif communicate via TLR7 and TLR8 and induce 
cytokine secretion by TLR7- and TLR8-positive immunocytes. 
TLR8-specific RNA sequences trigger cytokine responses from 
bovine and human but not mouse, porcine, or rat immune cells, 
suggesting that the latter species lack the ability to properly 
respond to TLR8 RNA ligands. Thus, RNA sequences that 
induce specific TLR8-dependent immune responses must still 
be identified (27).
Some siRNAs use sequence-specific methods to act via TLR7/8 
pathways and activate IFN-β. Immunostimulatory motifs, such as 
5′-UGUGU-3′, 5′-GUCCUUCAA-3′, AU, UGGC, and GU, have 
been described on the siRNA sense strand (25, 27–33). Uridine/
adenosine and uridine/guanosine nucleotides within the immu-
nostimulatory RNA (isRNA) enable sensors for TLR8 and TLR7, 
respectively (12). Blunt-ended synthetic siRNAs use RIG-I to 
induce IFIT1 gene activation (34). TLR7/8-dependent cytokine 
production is triggered when uridine is present in RNA in a 
manner in which TLR7/8 agonist potency correlates with overall 
uridine moieties, while uridine replacement with adenosine 
abrogates the effect (31). Judge et al. reported that siRNAs created 
in non-viral delivery devices could be potent IFN and inflamma-
tory cytokine inducers both in vitro in human blood and in vivo 
in mice. The formulated siRNA immunostimulatory activity and 
associated toxicities are nucleotide sequence-dependent. The 
immunostimulatory motifs 5′-UGU-3′ and 5′-UGUGU-3′ were 
identified (28). When examined in PDCs, the nine bases at the 3′ 
end (5′-GUCCUUCAA-3′) of the siRNA sense strand controlled 
its immunostimulatory activity, the immunostimulatory com-
ponent of a strong IFN-α-inducing siRNA. Immunostimulation 
via siRNA was absent in mice lacking TLR7, which suggests that 
isRNA is identified in a TLR7-dependent and sequence-specific 
manner (25).
According to Sioud et  al., human PBMCs recognize and 
respond to numerous single-stranded siRNA, both sense and 
antisense. isRNA motifs are usually more easily recognized via 
single-stranded siRNA than siRNA duplexes. The replacement 
of novel isRNA motifs with adenosines abrogated the immune 
activation. Interestingly, replacement of 2′-hydroxyl uridines 
with 2′-fluoro, 2′-O-methyl, or 2′-deoxy uridines blocked the 
immune activation. Thus, RNA immune recognition by TLRs 
can be prevented using 2′-ribose modifications of uridines (31).
The transfection of siRNAs causes IFN-mediated Jak–
Stat pathway activation and global ISG upregulation. This 
effect is mediated through PKR protein kinase, which is 
dsRNA- dependent, activated by 21-bp siRNA sequences, and 
is required for siRNA-induced IFN-β upregulation. The RNAi 
mechanism is not dependent on the IFN system, as shown in cell 
lines lacking the specific components that mediate IFN action 
(13). The deletion of one nucleotide from the siRNA sequence 
prevented OAS1 induction, which suggests that its underlying 
mechanism involves a detector that can identify 19- but not 14-bp 
RNA constructs (35).
A summary of information related to the sequence-dependent 
stimulation of cellular pathways by siRNAs is given in Table 1.
veCTOR-ASSOCiATeD iMMUNe 
STiMULATiON
Bridge et  al. showed that a frequently used shRNA sequence 
that includes plasmid and lentiviral systems can induce an IFN 
response and recommended IFN induction testing prior to 
declaring a target-specific effect. The use of the lowest effective 
shRNA vector dose is a simple way to limit the risk of stimulating 
an IFN response (14).
Pebernard and Iggo showed that shRNA-expressing lenti-
viral vectors with the U6 promoter more frequently exhibited 
ISG induction than lentiviral vectors using the H1 promoter. 
Further studies revealed that ISG induction was partially 
induced by an AA di-nucleotide near the transcription start 
site. A lamin shRNA was found to induce OAS1 when fused to 
VA RNA I, which can inhibit PKR, independent of U6 or H1 
promoters (35). The use of lentiviral vectors to deliver shRNA 
of 21-mers or more to silence the plasminogen activator 
inhibitor-2 mRNA increased OAS1 expression and decreased 
the lentiviral vector titer needed to reduce shRNA expression 
and OAS1 induction without majorly impacting gene silencing 
efficacy (40).
In vivo studies have shown that peptide siRNA conjugates 
can induce unwanted immune responses. Also, siRNAs targeting 
p38 MAP kinase conjugated with penetratin, but not cholesterol 
or TAT (48–60), activated an innate immune response, likely 
via TLR3, TLR7, and/or TLR8 activation (31, 41). Significantly 
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increased TNF-α and IL-12 p40 expressions and increased IFN-α 
release were observed after the intratracheal administration of 
penetratin–siRNA but not penetratin or siRNA alone, suggesting 
that penetratin-mediated siRNA delivery is accomplished differ-
ently from those of cholesterol and TAT conjugates or that the 
individual conjugates enter the cytosol and experience various 
biochemical outcomes (41).
RNAi-DiReCTeD iMMUNe 
STiMULATiON
Interestingly, in an RNAi study of WHV-infected PWHs, the 
RNAi-mediated WHV suppression enhanced inflammatory 
cytokine as well as MxA and MHC-I cellular gene expressions. 
The increased MHC-I and MxA expressions were identified in 
WHV-infected but not naïve PWHs, excluding the sequence-
dependent immune stimulation of the siRNAs. In addition, 
MHC-I and MxA expression upregulation was observed when 
the siRNAs effectively degraded WHV RNAs, and the more effec-
tive the siRNAs, the higher the MxA and MHC-I induction levels. 
These data suggested that specific siRNAs inhibit the replication 
of hepadnaviruses but induce the cellular gene expressions that 
antiviral activity requires (16).
Further studies have shown that specific siRNAs targeting 
WHV as well as host genes such as mouse β-actin and GAPDH 
can upregulate the mRNA expressions of MxA, IFN-β, and IP-10 
as well as reduce targeted mRNA expression. The enhanced 
ISG and inflammatory cytokine expressions were enhanced by 
viral and host gene silencing; an RNAi inhibitor disrupted ISG 
upregulation, but the lack of RNAi targets resulted in no ISG 
induction. Thus, immune stimulation under these circumstances 
must be mediated via RNAi or related factors and most likely by 
cleaved components resulting from the RNAi process. The RNAi-
mediated immune stimulation was abolished using inhibitors for 
TLR3/7/8 and PKR signaling pathways but not RIG-I/MDA5 
interference (17).
Collectively, these findings demonstrate that RNAi triggers 
immune activation via the TLR3/7/8 and PKR cascades. The 
so-called GU-rich non-self-RNA molecules compose RNAi-
generated small viral RNA cleaved components that can upregu-
late antiviral RNAi via PKR and TLR3/7/8 signaling (Figure 1) 
(17).
OveRCOMiNG THe CHALLeNGeS OF 
RNAi-ASSOCiATeD iNNATe iMMUNiTY 
STiMULATiON
Because RNAi-associated immune stimulation reflects special 
siRNA sequences, siRNA delivery vehicle types, and RNAi-
directed RNA cleavage products, it is possible to create strategies 
of avoiding RNAi-associated immune activation. First, known 
immunostimulatory motifs, such as 5′-UGU-3′, 5′-UGUGU-3′ 
(28), and 5′-GUCCUUCAA-3′ (25), should be lacking from the 
non-stimulatory siRNA sequences. Second, fewer immunostim-
ulatory vectors should be selected for siRNA delivery. Third, a 
reduction in the number of siRNAs can attenuate RNAi-directed 
immune activation.
Designing Non-Stimulatory siRNAs
Modification of siRNAs
Using the appropriate modification may enable siRNA-associated 
immune activation evasion without reducing RNAi potency. Base 
modifications can reduce immune activation, and the addition 
of modified nucleotides into siRNA suppresses unwanted immu-
nostimulation. Morrissey et al. reported that the use of various 
2′-modified nucleotides, including DNA bases, 2′-O-methyl 
purines, 2′-fluoropyrimidines, PS linkage modifications, and 
terminal inverted-dT bases at certain points could prevent siRNA 
immune activation (42). The use of 2-thiouracil or pseudouracil 
prevents immunostimulation mediated by RIG-I, reflecting the 
5′-triphosphate (43), while 5-methyl-C and N6-methyl-A 
pseudouridine prevent RNA recognition by TLR3, TLR7, and 
TLR8 (44). Interestingly, RNA with 2′-ribose modifications, 
2′-O-methyl in particular, avoided immune activation and 
suppressed the trans configuration-induced TLR signaling via 
isRNAs. The 2′-O-methyl modifications on siRNAs avoid TLR-
mediated in vivo and in vitro hepatic immune system activation 
(45). The addition of 2′-O-Me guanosine or uridine into the 
siRNA sense strands creates non-inflammatory siRNAs without 
interfering ability loss but can selectively protect the vulnerable 5′ 
end of the guide strand from the effects of human serum-derived 
exonucleases (46).
The chemical influences preventing immune system activa-
tion must be carefully implemented to ensure siRNA-silencing 
activity. The replacement of uridine bases only with 2′-fluoro-, 
2′-deoxy-, or 2′-O-methyl-modified counterparts can abrogate 
TLR siRNA immune recognition without reducing the potent 
siRNA-silencing activity (31, 47). Also, 2′-uridine-modified 
ssRNAs did not activate innate human immunity within 
blood cells (31), and the exchange of uridines and thymidines 
in the siRNA sense strand did not prevent siRNA silencing 
but inhibited innate immunity activation (48). The 2′-O-Me 
siRNAs targeting apolipoprotein B (apoB) and containing 
<20% modified nucleosides can facilitate potent target mRNA 
silencing and significantly decrease serum apoB and choles-
terol levels (47).
Although 2′-modified RNA strands can prevent immune acti-
vation, those that are naturally modified might be unrecognized 
by TLR7/8 (49). The inhibition of endosome acidification via 
chloroquine and bafilomycin A1 can block the TLR3-, TLR7-, 
and TLR8-directed immunological activities of siRNAs without 
impacting the effect of RNAi (24, 50).
Studies in human monocytes have shown that even low 
2′-O-methyl-modified RNA concentrations can prevent isRNA-
induced TLR7 activation (9, 50). Chemically enhanced RNA can 
provoke isRNA and induce production of the immunosuppres-
sive enzyme indoleamine 2,3-dioxygenase (IDO) (51). Robbins 
et  al. reported that 2′-modified isRNAs antagonize TLR7/8 by 
abrogating isRNA-induced TLR signaling or loxoribine in both 
human and murine cells (52). Suppressive 2′-modified RNAs 
may comprise a new agent class for treating TLR8 and TLR7 
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signaling-triggered autoimmunity. Since TLRs are not bound 
by thymidine-modified siRNAs and 2′-deoxyuridines, such a 
change should be able to preserve TLR function and prevent 
immune activation (50).
eNHANCiNG RNAi iMMUNe ACTiviTY
Potential Benefits of immunostimulatory 
siRNA (isiRNA) Use
Undesired activity of immunosuppressive cytokines and other 
negative regulators are expected to negatively impact immunity 
against tumors and virus-infected cells (53). Therefore, stimula-
tors of immune and/or virus-infected cells that produce IFN 
and/or Th1 cytokines and can prevent cancer and viral-specific 
immune tolerance and restore immune surveillance in cases of 
cancer and viral infections are needed.
Stimulation with isRNA can induce the maturation of DCs 
and subsequent cytokine secretion, including IL-6 and IL-12, 
both of which are essential to CD4+ effector T cell- and Th1-type 
responses (24). Hyperactive bifunctional siRNAs targeting IDO, 
a key factor involved in immune suppression, can abrogate its 
genetic expression in human DCs and monocytes. Interestingly, 
when transfected with siRNA bearing 5′-triphosphate, immature 
monocyte-derived DCs activate T  cells, showing that the DCs 
were mature enough to initiate T-cell activation, even without 
external stimuli. Taken together, these findings demonstrate that 
RNAi technology can regulate T-cell growth and development 
processes (50). Patients with cancer who were vaccinated with 
DC vaccines lacking IDO demonstrated this kind of clinical 
response (54).
Rational Design of isiRNAs
Short RNA Structural and Sequence Requirements 
for Activating TLR7/8
The ability of short RNAs to sense TLR7/8 is uridine-dependent, 
and the residue positions of uridine within the secondary ssRNA 
structure could affect immunostimulation (7). As uridine lev-
els increased, IFN-α and TNF-α were induced. At the ssRNA 
dose of 90 nmol/L, immunostimulation required four or more 
uridines. However, the use of eight or more uridines did not 
further increase the cytokine production. Collectively, these 
results suggest that the uridine content and secondary structure 
are involved in TLR7/8 sensing of ssRNAs (39). The combina-
tion of the immunostimulatory sequence (5′-UGUGU-3′) and 
western blot analysis of NP-specific siRNA revealed a strong 
antiviral effect of the isiRNA via a reduction in the number of 
mRNA copies (99.58%), virus-associated cell apoptosis, and 
nucleocapsid protein inhibition. The use of isiRNA was more 
effective than non-tagged siRNA, while the higher antiviral 
response of isiRNA reflected the upregulation of TLR7, MyD88, 
IRF7, and IFN-α (55).
miRNA-Like siRNA
Gantier et al. observed that the addition of anon-pairing uridine 
bulge similar to miRNA in the passenger strand of siRNAs greatly 
increased human immune cell immunostimulatory activity. In 
immunostimulatory assays, a comparison of the EGFP siRNA 
with or without bulge modification in immunostimulatory assays 
revealed greatly increased TNF-α induction (>10-fold at 500 and 
750  nmol/L) and significantly greater IFN-α (at 500  nmol/L) 
induction. This bulge did not affect RNAi triggering of the EGFP 
siRNA in stable EGFP-expressing HEK 293T cells. The human 
papilloma virus 16 E6/E7 oncogene showed similar results. 
These results collectively demonstrate that different designs of 
the uridine bulge can greatly increase TNF-α and IFN-α expres-
sions in human PBMCs independent of the siRNA sequence 
without preventing siRNA from entering the RNAi pathway 
(39). A protein array analysis of multiple cytokines confirmed the 
marked upregulations of TNF-α, IL-12 (p70), IL-1β, and IFN-γ 
and induced by the uridine bulge modification. G-CSF, GM-CSF, 
IL-4, IL-5, IL-7, IL-10, and IL-17 were significantly induced in 
two of three analyzed siRNAs. Due to the increased IFN-α pro-
duction, the uridine modification of siRNA predictably provided 
significant protection against Semliki Forest virus infection com-
pared to native siRNA, while the uridine bulge modification of 
21-bp siRNA siβ-Gal significantly induced TNF-α and IFN-α in 
human PBMCs compared to the native variant (39). These results 
indicate that the uridine content increases, structural distortion, 
and bulge modification induced cytokine production. These data 
suggest that this combination of structural and sequence modi-
fications specifically recruits human TLR8 versus TLR7 and may 
contribute to antiviral therapies (39).
5′-Triphosphate-Modified siRNA
The addition of 5′-triphosphate (3p) to the siRNAs generated 
ligands for RIG-I, which subsequently became activated and 
induced type I IFN expression. The results showed that 3p-siRNAs 
(5′-end triphosphate siRNA) induced an antiviral type I IFN 
response that was dependent on RIG-I in HBV-infected primary 
human hepatocytes, HepG2.2.15 cells, and HBV transgenic mice 
(36–38). The 3p-siRNAs showed more pronounced and long-term 
suppression of HBV DNA replication and mRNA transcription 
than normal siRNAs targeting the same sequences, suggesting 
that 3p-siRNA might be a powerful antiviral molecule and poten-
tial therapeutic agent for treating chronic HBV infection (38).
Survivin, a new apoptosis inhibitor family member, is upregu-
lated in human lung cancer and other malignancies. Studies 
in human lung cancer cells demonstrated that the 3p-siRNA 
targeting human survivin gene (3p-survivin-siRNA) induced a 
3p-dependent type I IFN response and significantly downregu-
lated lung cancer cell proliferation. In fact, its cancer-inhibiting 
effect exceeded that of conventional siRNA. Used with radio-
therapy, 3p-survivin siRNA upregulates A549 cell cytotoxicity 
and increases the frequency of apoptosis (56). Using Bcl2-specific 
3p-siRNA against melanoma, RIG-I signaling pathway activities 
mediated by 3p-siRNA combined with siRNA-mediated Bcl2 
abrogation to induce massive metastasized lung tumor cell apop-
tosis. This effect in vivo required Bcl2 silencing, IFN, and natural 
killer cells as evidenced by rescuing with Bcl2 target mutation 
via Bcl2 mRNA site cleavage in lung metastases and Bcl2 protein 
downregulation in tumor cells (57).
Collectively, these findings show that 3p-siRNAs can act as 
powerful bifunctional molecules with RIG-I activation and 
FiGURe 2 | Schematic representation of isiRNA and non-isiRNA. RNA 
sequence requirements of isiRNA and non-isiRNAs were shown; isiRNA may 
trigger toll-like receptor (TLR) 7/8, or retinoic acid-inducible gene-I (RIG-I)/
melanoma differentiation-associated protein 5 (MAD5) signaling pathways, 
leading to activation of innate immunity. isiRNA, immunostimulatory siRNA; 
non-isiRNA, non-stimulatory siRNA.
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targeting knockdown and the potential to antagonize cancer and 
viral infections. isiRNAs enhance innate immunity levels and 
silence target genes in a sequence-specific manner, which gives 
RNAi a dual-action approach that directly targets knockdown and 
immunoenhancing activity. Thus, isiRNA may be tightly involved 
in antagonizing cancers and viral infections. RNA sequence 
requirements of isiRNA and rational design of non-stimulatory 
siRNAs were shown in Figure 2.
CONCLUSiON
The sequences of siRNA, the siRNA delivery vehicles, and the 
secondary RNAi products contribute to immune stimulation 
characterized by enhanced IFN and/or pro-inflammatory 
cytokine creation using the PKR, RIG-I, or TLR3/7/8 signaling 
pathways. Most of these immunostimulatory activities were con-
sidered off-target adverse effects; thus, non-stimulatory siRNAs 
are still needed. In other circumstances, immune stimulation is 
beneficial and isiRNAs with both RNAi and immunostimulatory 
activities may represent novel agents for treating cancers and viral 
infections.
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